Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2005

01-08-2005

Enhanced P53 and BAX gene expression and apoptosis in A549 cells by cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP

Authors: Beata Kosmider, Izabela Wojcik, Regina Osiecka, Jacek Bartkowiak, Elzbieta Zyner, Justyn Ochocki, Pawel Liberski

Published in: Investigational New Drugs | Issue 4/2005

Login to get access
Metadata
Title
Enhanced P53 and BAX gene expression and apoptosis in A549 cells by cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP
Authors
Beata Kosmider
Izabela Wojcik
Regina Osiecka
Jacek Bartkowiak
Elzbieta Zyner
Justyn Ochocki
Pawel Liberski
Publication date
01-08-2005
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 4/2005
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-005-1437-z

Other articles of this Issue 4/2005

Investigational New Drugs 4/2005 Go to the issue

OriginalPaper

BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR)

OriginalPaper

A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines

OriginalPaper

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

Erratum

Pomegranate (Punica granatum) Pure Chemicals Show Possible Synergistic Inhibition of Human PC-3 Prostate Cancer Cell Invasion Across Matrigeltm

OriginalPaper

A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer

OriginalPaper

Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits